Triflubazam
From Wikipedia, the free encyclopedia
|
Triflubazam
|
|
| Systematic (IUPAC) name | |
| 5-methyl-1-phenyl-8-(trifluoromethyl)-1,5-benzodiazepine-2,4-dione | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C17H13F3N2O2 |
| Mol. mass | 334.29 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Triflubazam is a drug which is a 1,5-benzodiazepine derivative, related to clobazam. It has sedative and anxiolytic effects, with a long half-life and duration of action.[1][2][3]
[edit] References
- ^ Itil TM, Akpinar S, Fink M: Controlled clinical and quantitative EEG studies of triflubazam (ORF 8063) in patients with anxiety syndrome. Current Therapeutic Research 1976; 19: 307-315
- ^ Csanalosi I, Pereira-Oran J, Case G, et al: Triflubazam (ORF 8063), a new benzodiazepine in anxiety neurosis. Current Therapeutic Research 1977; 22: 166-171
- ^ Nicholson AN, Stone BM, Clarke CH. Effect of the 1,5-benzodiazepines, clobazam and triflubazam, on sleep in man. British Journal of Clinical Pharmacology. 1977 Oct;4(5):567-72.
|
|||||||||||||||||||||||||||||

